Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Chief Renews Call for Reflecting Inflation and Wage Hikes in Drug Pricing
Japan Pharmaceutical Manufacturers Association (JPMA) President Asuka Miyabashira reiterated the group’s call for a review of the government’s spending ceiling on social security, ahead of budget debates expected to heat up towards the year-end. Speaking at a press conference on…
To read the full story
Related Article
- JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
- JPMA Exec Urges Immediate Action on Inflation Pressures as Budget Talks Loom
November 14, 2025
ORGANIZATION
- Pharma Labor Group Logs Wage Hikes of around 4% at July-End
August 24, 2026
- Biotech Group Calls for Post-IPO Startups to Get AMED Support
August 19, 2026
- EFPIA Executive Hails Japan’s Honebuto as “Blueprint” for Europe
August 17, 2026
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…